Lupin Limited (NSE: LUPIN) receives U.S. FDA approval for Diazepam Injection USP, expanding its therapeutic offerings.
Lupin Limited (LUPIN) announces U.S. FDA approval and launch of Sugammadex Injection, a bioequivalent to Bridion®.
Lupin Limited (NSE: LUPIN) has been recognized among India’s Best Employers in the Nation Builders Category by Great Place To Work® India for 2026.
Lupin Limited, NSE: LUPIN, recognized as one of the world’s most sustainable companies in 2026 by TIME and Statista.
Lupin Limited (LUPIN) secures EMA approval for expanded pediatric indication for NaMuscla®, broadening access to treatment for non-dystrophic myotonic disord.
Lupin Limited (LUPIN) secures tentative approval from U.S. FDA for Enzalutamide Tablets, expanding dosage options.
Lupin Limited (NSE: LUPIN) launches Azilsartan Medoxomil Tablets in the U.S., following FDA approval, to treat hypertension.
Lupin Limited partners with LABORATORIOS ERN S.A. to launch Luforbec® in Spain, expanding respiratory care access.
Lupin Limited (LUPIN) and Natco Pharma receive FDA approval for Eribulin Mesylate Injection, a bioequivalent to Halaven®.
Lupin Limited (NSE: LUPIN) secures U.S. FDA approval for Sodium Sulfate, Magnesium Sulfate, and Potassium Chloride Tablets, marking a significant milestone.